<DOC>
	<DOCNO>NCT02233543</DOCNO>
	<brief_summary>The purpose study determine whether fix dose combination indacaterol glycopyrronium ( QVA149 ) impact night-time blood oxygen level Chronic Obstructive Pulmonary Disease .</brief_summary>
	<brief_title>A Multicenter , 4-week Crossover ( Total Duration 12 Weeks ) Determine Impact QVA149 Nocturnal Oxygen Levels Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Clinical diagnosis COPD ( accord GOLD guideline , updated 2014 ) postbronchodilator FEV1/FVC &lt; 0.70 Patients postbronchodilator FEV1 ≥30 % &lt; 60 % predict normal value Resting daytime oxygen saturation level measure pulse oximetry ≤95 % SpO2 Smoking history least 10 pack year ( Ten packyears define 20 cigarette day 10 year , 10 cigarette day 20 year ) An exacerbation COPD ( treatment oral parenteral antibiotic and/or glucocorticosteroids and/or hospitalization relate COPD ) within 4 week prior screen runin period Diagnosed asthma Patients receive regular long term oxygen therapy ( LTOT ) Ongoing / plan rehabilitation study period Three awakening night lead toilet visit reason exit bed last week prior screen visit due nonCOPD reason Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>QVA149</keyword>
	<keyword>nocturnal oxygen level</keyword>
	<keyword>combination bronchodilator</keyword>
</DOC>